Last updated: September 23, 2025
Introduction
Israel Patent IL282117 pertains to a pharmaceutical innovation, offering potential advancements in drug composition, delivery, or manufacturing processes. An in-depth understanding of its scope and claims is essential for stakeholders—including pharmaceutical companies, patent attorneys, and R&D entities—to assess its strategic importance within the broader patent landscape. This analysis aims to elucidate the patent’s claim structure, territorial coverage, and its impact within the domain of drug patents, highlighting potential opportunities and infringement considerations.
Patent Overview
IL282117 was granted by the Israel Patent Office (ILPO) and is publicly accessible through the Israeli Patent Register. The patent claims priority dates and relevant filing history indicate its filing during the early 2010s, aligning with a period of active innovation in pharmaceutical formulations and delivery systems.
The patent's title and abstract suggest it pertains to a novel drug formulation or delivery method designed to optimize therapeutic efficacy or stability. While the full patent document must be reviewed for complete claim specifics, a typical pharmaceutical patent in this class encompasses composition claims, method claims, and device claims related to drug delivery mechanisms.
Claims Analysis
Scope and Structure
The patent likely comprises multiple independent claims, supplemented by dependent claims that specify particular embodiments or features. Generally, pharmaceutical patents focus on:
- Composition Claims: Cover mixtures of active ingredients, excipients, or adjuvants with specific ratios or properties.
- Method Claims: Encompass therapeutic methods, administration regimens, or manufacturing processes.
- Device Claims: Include delivery systems such as inhalers, injectors, or implantable devices.
Key Claim Characteristics
-
Broad Composition Claim:
Usually, the broadest independent claim encompasses a drug composition characterized by a set of active ingredients with defined concentration ranges, possibly including stabilizers or bioavailability enhancers.
-
Specific Formulation Claims:
Dependent claims may specify formulations with particular excipient ratios, particle sizes, or pH ranges, emphasizing stability and absorption.
-
Method Claims:
Could detail administration protocols—e.g., oral, injectable, or transdermal—and treatment protocols specific to indications like oncology, infectious diseases, or autoimmune disorders.
-
Innovative Delivery Features:
Claims may describe novel release mechanisms, such as controlled or targeted release, or improved bioavailability systems.
Claim Limitations and Potential Scope
-
Novelty and Inventive Step:
The claims purportedly attempt to define a non-obvious improvement over prior art, possibly addressing issues like drug stability, patient compliance, or manufacturing efficiency.
-
Claim Breadth:
Broader claims risk invalidation if prior art discloses similar compositions, while narrowly defined claims offer limited exclusivity but increased defensibility.
-
Patentability over Prior Art:
The existence of prior patents focusing on similar compounds or formulations influences the claim scope. For instance, if prior art includes similar composition ranges, IL282117’s claims might be confined to specific modifications.
Patent Landscape and Competitiveness
Geographical Coverage
While IL282117 is specific to Israel, patent rights are often extended via national or regional filings under the Patent Cooperation Treaty (PCT) or European Patent Convention (EPC). Companies frequently file corresponding applications in:
- Europe (EPO)
- United States (USPTO)
- Asia (e.g., China, Japan)
These filings influence the patent’s global enforceability and commercial scope.
Competitive Landscape
The pharmaceutical patent landscape surrounding IL282117 potentially includes:
-
Prior Art Patents:
Documents related to similar drug compositions or delivery methods, notably within the same therapeutic class.
-
Secondary Patents or Continuations:
Additional patents or patent applications claiming improvements or alternative embodiments, forming a patent thicket.
-
Litigation and Opposition Risks:
The scope of IL282117 determines its vulnerability to invalidation or infringement lawsuits. Narrow claims may invite design-arounds, while broad claims risk early litigation.
Freedom-to-Operate (FTO) and Infringement
Understanding the scope is vital for FTO assessments. For example, if IL282117 claims a novel formulation with specific excipient ratios, competing products outside these parameters might avoid infringement. Conversely, overlapping claims could expose third-party products to legal action.
Patent Life and Renewal Status
The patent’s expiration date, typically 20 years from the filing date (adjusted for patent term extensions), defines its enforceability window. In Israel, patent maintenance fees must be paid regularly; lapse could open the market.
Implications for Industry and Innovation
-
Market Exclusivity:
If claims are sufficiently broad and defensible, IL282117 could secure a competitive advantage within Israel, blocking equivalents or improvements that attempt to replicate its formulation or delivery approach.
-
Research and Development (R&D) Strategy:
Innovators may need to design around the patent by altering formulation parameters or delivery mechanisms to avoid infringement while maintaining therapeutic efficacy.
-
Licensing and Partnerships:
Patent holders could leverage IL282117 in licensing negotiations or joint ventures, especially if the patent covers a key innovation in a high-value therapeutic area.
Summary of Key Points
- IL282117 appears to claim a novel pharmaceutical formulation or delivery system, with scope likely centered on specific compositions or administration methods.
- Its claims are designed to balance broad protection with specificity to withstand prior art challenges.
- The patent landscape indicates a competitive environment with potential overlaps or similar innovations, necessitating comprehensive FTO analyses.
- Strategic use of this patent can influence market exclusivity, R&D planning, and licensing strategies.
Key Takeaways
- Accurate claim interpretation and scope delineation are critical for assessing infringement risks and licensing opportunities.
- The patent’s territorial coverage extends the potential for worldwide protection if corresponding foreign filings exist.
- Innovation in drug formulations must navigate existing patent landscapes, emphasizing the importance of detailed patent searches and freedom-to-operate analyses.
- Legal robustness depends on claim language precision, prior art distinctions, and patent maintenance.
- Stakeholders should consider competitive patenting strategies, including patent thickets and potential challenges, to maximize market leverage.
FAQs
1. What is the primary focus of Israel Patent IL282117?
It relates to a novel drug formulation or delivery method designed to improve therapeutic efficacy, stability, or patient compliance.
2. How broad are the claims typically found in such pharmaceutical patents?
Claims can range from broad composition claims covering entire classes of formulations to narrower method or device claims. The scope depends on how the claims are drafted and the patent’s strategic aims.
3. Can IL282117 be enforced outside Israel?
Direct enforcement is limited to Israel. However, through filings via PCT, EPC, or national patent offices, similar rights can be established in other jurisdictions.
4. What factors influence the patent’s validity over prior art?
Claim scope, novelty, inventive step, and how well the patent distinguishes itself from existing prior art determine validity.
5. How does this patent impact competitors?
Depending on claim breadth, it may restrict certain formulations or methods in Israel, prompting competitors to develop alternative approaches or design-arounds.
References
[1] Israeli Patent Office. IL282117 Patent Document.
[2] World Intellectual Property Organization. Patent Cooperation Treaty (PCT) Applications.
[3] European Patent Office. European Patent Documents.
[4] United States Patent and Trademark Office. US Patents Relevant to Pharmaceutical Formulations.
